At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 124 enrolled
Drug / intervention
Open Label (OL) Paroxetine +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Placebo-controlled Trial of Adjunctive Quetiapine for Refractory PTSD
In Brief
A Phase 4 clinical trial evaluating Open Label (OL) Paroxetine, Placebo, and 1 other intervention for Combat Disorders and Stress Disorders, Post-Traumatic. Completed, enrolled 124 participants across 3 sites.
Detailed Summary
The purpose of this study is to compare the response of veterans with PTSD without an optimal response to paroxetine to quetiapine augmentation versus placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCombat Disorders, Stress Disorders, Post-Traumatic
CountriesUnited States
CollaboratorsAstraZeneca
Timeline
Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2006
First PostedFeb 2006
Primary CompletionDec 2008
Study CompletionMay 2009
TodayJul 2026
First PostedFeb 15, 2006
Enrollment StartJan 1, 2006
Primary CompletionDec 1, 2008
Study CompletionMay 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 20.4 years ago
Interventions
Open Label (OL) Paroxetinedrug
Open-label Paroxetine
Placebodrug
Double-blind placebo taken with OL paroxetine
Quetiapinedrug
Double-blind quetiapine taken with OL paroxetine